{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:52:35Z","timestamp":1753883555006,"version":"3.41.2"},"reference-count":27,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 62-year-old Sudanese female was diagnosed with a nonfunctioning pituitary adenoma in 2006. Despite undergoing 3 transsphenoidal surgeries and radiotherapy, her tumor persisted, causing debilitating symptoms, including headaches and visual defects. As a last resort, she was treated with pasireotide, a second-generation somatostatin analog with a broader receptor affinity than first-generation drugs. Over 6 months, the tumor mass was stabilized, and her symptoms, including headaches, disappeared. This case demonstrates a potential new therapeutic possibility for treating resistant pituitary adenoma with pasireotide, offering hope for patients when traditional treatments fail.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf075","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T15:34:21Z","timestamp":1744990461000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Volume Control of Invasive Pituitary Adenoma Tumor With Pasireotide: A New Horizon for a Challenging Disease"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3451-503X","authenticated-orcid":false,"given":"Tarik","family":"Elhadd","sequence":"first","affiliation":[{"name":"Pituitary Clinic, Endocrine Section, Department of Medicine, Hamad General Hospital, Hamad Medical Corporation , P.O. Box 3050, Doha ,","place":["Qatar"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahd I","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Pituitary Clinic, Endocrine Section, Department of Medicine, Hamad General Hospital, Hamad Medical Corporation , P.O. Box 3050, Doha ,","place":["Qatar"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elabbass","family":"Abdelmahmuod","sequence":"additional","affiliation":[{"name":"Pituitary Clinic, Endocrine Section, Department of Medicine, Hamad General Hospital, Hamad Medical Corporation , P.O. Box 3050, Doha ,","place":["Qatar"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M","family":"Webb","sequence":"additional","affiliation":[{"name":"Department of Medicine, Univ Autonoma Barcelona, Research Center for Pituitary Diseases, Institut de Recerca Sant Pau (IIB-Sant Pau) and CIBERER Unit 747, ISCIII, Department of Endocrinology, Hospital S Pau , Barcelona 08025 ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"issue":"6","key":"2025042313221484600_luaf075-B1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3803\/EnM.2023.1838","article-title":"Update on current evidence for the diagnosis and management of nonfunctioning pituitary neuroendocrine tumors","volume":"38","author":"Whyte","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"10","key":"2025042313221484600_luaf075-B2","doi-asserted-by":"crossref","first-page":"R375","DOI":"10.1530\/ERC-20-0136","article-title":"The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)","volume":"27","author":"Yavropoulou","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2025042313221484600_luaf075-B3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/biomedicines9050494","article-title":"Pituitary adenomas: from diagnosis to therapeutics","volume":"9","author":"Banskota","year":"2021","journal-title":"Biomedicines"},{"issue":"(07|7)","key":"2025042313221484600_luaf075-B4","first-page":"443","article-title":"Natural history of non-functioning pituitary adenomas: a systematic review and meta-analysis","volume":"55","author":"Rikvold","year":"2023","journal-title":"Horm Metab Res"},{"issue":"7","key":"2025042313221484600_luaf075-B5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.endinu.2017.05.009","article-title":"Clinically non-functioning pituitary adenomas: pathogenic, diagnostic and therapeutic aspects","volume":"64","author":"Mercado","year":"2017","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"4","key":"2025042313221484600_luaf075-B6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11102-011-0370-8","article-title":"Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study","volume":"15","author":"Fusco","year":"2012","journal-title":"Pituitary"},{"author":"Anon","key":"2025042313221484600_luaf075-B7"},{"author":"Anon","key":"2025042313221484600_luaf075-B8"},{"key":"2025042313221484600_luaf075-B9","first-page":"EP796","article-title":"Octreotide and pasireotide LAR in non-functioning pituitary neuroendocrine tumours treatment","volume":"90","author":"Bogus\u0142awska","year":"2023","journal-title":"Endocr Abstr"},{"key":"2025042313221484600_luaf075-B10","first-page":"EP1145","article-title":"Pasireotide LAR treatment for non- functioning pituitary adenoma: a case report","volume":"90","author":"Menotti","year":"2023","journal-title":"Endocr Abstr"},{"author":"Drummond","key":"2025042313221484600_luaf075-B11"},{"issue":"1","key":"2025042313221484600_luaf075-B12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1530\/ERC-14-0472","article-title":"SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary","volume":"22","author":"Lee","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2025042313221484600_luaf075-B13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-19-2154","article-title":"A somatostatin receptor subtype-3 (SST(3)) peptide agonist shows antitumor effects in experimental models of nonfunctioning pituitary tumors","volume":"26","author":"V\u00e1zquez-Borrego","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025042313221484600_luaf075-B14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","author":"Colao","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2025042313221484600_luaf075-B15","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3390\/ijms21051682","article-title":"Somatostatin analogs in clinical practice: a review","volume":"21","author":"Gomes-Porras","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2025042313221484600_luaf075-B16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","author":"Ib\u00e1\u00f1ez-Costa","year":"2016","journal-title":"J Endocrinol"},{"issue":"1","key":"2025042313221484600_luaf075-B17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1677\/ERC-06-0026","article-title":"Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion","volume":"14","author":"Zatelli","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"2025042313221484600_luaf075-B18","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.3390\/cancers13123097","article-title":"Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in vivo model of nonfunctioning pituitary tumors","volume":"13","author":"Gulde","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025042313221484600_luaf075-B19","doi-asserted-by":"crossref","first-page":"bcr2017219686","DOI":"10.1136\/bcr-2017-219686","article-title":"Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches","volume":"2018","author":"Lovato","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"8","key":"2025042313221484600_luaf075-B20","doi-asserted-by":"crossref","first-page":"luae142","DOI":"10.1210\/jcemcr\/luae142","article-title":"Rapid resolution of recalcitrant headache with pasireotide in an adult patient with acromegaly","volume":"2","author":"Dabbous","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"2","key":"2025042313221484600_luaf075-B21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11102-018-0865-7","article-title":"Management of NFAs: medical treatment","volume":"21","author":"Even-Zohar","year":"2018","journal-title":"Pituitary"},{"issue":"2","key":"2025042313221484600_luaf075-B22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11102-016-0745-y","article-title":"How effective is temozolomide for treating pituitary tumours and when should it be used?","volume":"20","author":"Halevy","year":"2017","journal-title":"Pituitary"},{"issue":"3","key":"2025042313221484600_luaf075-B23","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jc.2012-2924","article-title":"DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan society for hypothalamic and pituitary tumors","volume":"98","author":"Hirohata","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2025042313221484600_luaf075-B24","doi-asserted-by":"crossref","first-page":"1204206","DOI":"10.3389\/fendo.2023.1204206","article-title":"Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain","volume":"14","author":"Lamas","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2025042313221484600_luaf075-B25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00259-019-04578-z","article-title":"An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy","volume":"47","author":"Assadi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2025042313221484600_luaf075-B26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","article-title":"Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma","volume":"17","author":"Komor","year":"2014","journal-title":"Pituitary"},{"issue":"6","key":"2025042313221484600_luaf075-B27","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","article-title":"Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation","volume":"17","author":"Maclean","year":"2014","journal-title":"Pituitary"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/6\/luaf075\/62954725\/luaf075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/6\/luaf075\/62954725\/luaf075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:22:24Z","timestamp":1745428944000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf075\/8116176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4,18]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf075","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,18]]},"article-number":"luaf075"}}